Trial Profile
AN OPEN-LABEL, RANDOMIZED PROSPECTIVE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CAMPATH-1H AS AN INDUCTION AGENT IN COMBINATION WITH LOW DOSE-TACROLIMUS, LOW DOSE MMF AND REDUCED STEROID THERAPY COMPARED TO ATG-INDUCTION IN COMBINATION WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS THERAPY IN DE NOVO LUNG TRANSPLANTED PATIENTS.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jul 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin (Primary) ; Mycophenolate mofetil; Steroids; Tacrolimus
- Indications Transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUCIA
- 04 Jul 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 18 Aug 2011 New trial record